Product
Imx-110
1 clinical trial
6 indications
Indication
Solid TumorIndication
AdultIndication
CancerIndication
Pancreatic CancerIndication
Breast CancerIndication
Ovarian CancerClinical trial
A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-10-31